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TNF-related weak inducer of apoptosis (TWEAK) is a new member of the TNF superfamily. It signals through TNFRSF12A,
commonly known as Fn14. The TWEAK-Fn14 interaction regulates cellular activities including proliferation, migration,
diﬀerentiation,apoptosis,angiogenesis,tissueremodelingandinﬂammation.AlthoughTWEAKhasbeenreportedtobeassociated
with autoimmune diseases, cancers, stroke, and kidney-related disorders, the downstream molecular events of TWEAK-Fn14
signaling are yet not available in any signaling pathway repository. In this paper, we manually compiled from the literature, in
particular those reported in human systems, the downstream reactions stimulated by TWEAK-Fn14 interactions. Our manual
amassment of the TWEAK-Fn14 pathway has resulted in cataloging of 46 proteins involved in various biochemical reactions and
TWEAK-Fn14 induced expression of 28 genes. We have enabled the availability of data in various standard exchange formats
from NetPath, a repository for signaling pathways. We believe that this composite molecular interaction pathway will enable
identiﬁcation of new signaling components in TWEAK signaling pathway. This in turn may lead to the identiﬁcation of potential
therapeutic targets in TWEAK-associated disorders.
1.Introduction
TWEAK (TNFSF12) is a cell surface-associated type II trans-
membrane protein (249 amino acids) belonging to the
T u m o rN e c r o s i sF a c t o r( T N F )s u p e r f a m i l y[ 1]. Transmem-
brane TWEAK is processed into a secreted 156-amino-
acid form, which adopts a homotrimeric conformation. The
human TWEAK gene is located at chromosome 17p13.1 [1].
TWEAK mRNA has been reported to be expressed in
s e v e r a lt i s s u et y p e s ,s u c ha sh e a r t[ 2], brain [3, 4], kidney
[5, 6], and also in mononuclear blood cells [7]. Its protein
product has multiple biological activities, including stim-
ulation of cell growth and angiogenesis [8], induction of
inﬂammatory cytokines [9, 10] and stimulation of apoptosis
[11, 12]. It has been shown to be involved in the induction
of cellular proliferation in liver cells [13], osteoblasts [14],2 Journal of Signal Transduction
astrocytes [15], synoviocytes [16], kidney cells [17, 18], and
skeletal muscle [19]. TWEAK may also play a role in the cel-
lular diﬀerentiation of osteoclasts; however it remains con-
troversial whether this eﬀect is direct [20] or indirect, via
eﬀects on the osteoblastic stromal cell expression of RANKL
(TNFSF11)[ 21]. TWEAK also plays a role in inducing
glioma cell survival via imparting resistance to cytotoxic
agents [3, 22]. TWEAK serves a dual role in angiogenic reg-
ulation. It induces the endothelial cell survival and can be
a potential proangiogenic or antiangiogenic agent based
upon the presence of angiogenic promoting cytokines [8,
23]. Additionally, an apoptotic eﬀect of TWEAK has been
observed in endometrial cancers [24] and peripheral blood
monocytes [25, 26]. The apoptotic function of TWEAK ap-
pears to be mediated via the induced secretion of TNFα,
with the TNFα-TNFα receptor complex, thereafter inducing
autocrine cellular apoptosis by activating the RIPK1-FADD-
Caspase-8 complex [11, 27]. TWEAK was ﬁrst described as
an apoptotic factor by interacting with DR3 (TNFRSF25).
However, there were conﬂicting reports to the TWEAK-DR3
interaction [28, 29]. Hence, we chose to exclude TWEAK-
DR3 pathway analysis from our study. In addition, TWEAK
h a sb e e nr e p o r t e dt oi n t e r a c tw i t hC D 1 6 3[ 30]; however, the
downstream eﬀect of this interaction remains to be explored.
TNFRSF12A (tumor necrosis factor receptor super-
family, member 12A), also known as FGF-inducible 14 (Fi-
broblast Growth Factor-Inducible-14/Fn14), has been estab-
lished to date to be the major, if not sole, receptor for
TWEAK [12, 31, 32]. Fn14 is the smallest member of the
TNFR superfamily described so far, and it appears to signal
via recruitment of several diﬀerent TNFR-associated factors
[33]. This molecule has been reported to be expressed in
variety of organs including the heart [34, 35], kidney [6, 36],
and lung [37]. The cytoplasmic domain of Fn14, like other
members of the TNFR superfamily, does not contain con-
sensus amino acid sequences characteristic of domains with
enzymatic activity. TWEAK binds with high aﬃnity to
Fn14 [12, 31]. This interaction can stimulate a variety of
biological responses, depending on the cell type analyzed.
Winkles et al. (2008) hypothesized two modes of TWEAK-
Fn14 (ligand-receptor) interaction: (i) the ligand-dependent
interaction, which involves the higher concentration of
homotrimeric TWEAK, that binds to low concentration of
Fn14 in a heterohexameric complex [38, 39], and (ii) ligand-
independent interaction when the ligand concentration
is lower than the receptor concentration. Here, the free
receptors homotrimerize to activate the downstream events
[38]. Three notable signaling cascades have been reported
under TWEAK-Fn14 interactions. They are the canonical
and noncanonical NF-κBp a t h w a y s[ 21, 33, 34, 40]a n d
the MAPK pathway [41–43] with possible binding to TRAF
proteins.
The diﬀerential eﬀects of TWEAK on disease pathogen-
esis have been proposed by various groups. These diseases
include autoimmune disorders [16, 21, 44, 45], neurological
disorders [46, 47], periodontal disease [7], and cancers [3,
22, 24, 48–50]. Because of its multifunctional properties,
TWEAK is also being considered for use in therapeutics [51].
It is also being considered as a potential early and prognostic
biomarker for conditions such as kidney injury [52, 53], SLE
[54], atherosclerosis [55, 56], cardiovascular disorders [57–
59], immune preconception marker [60], and abdominal
aortic aneurysms [61]. Although the results obtained to
date are captivating, it is clear that additional studies are
required to determine whether TWEAK, and/or Fn14 could
be novel molecular targets for developing anticancer and
antiautoimmune therapeutic agents in humans.
Thus, given its importance in the ﬁeld of biomedical
research, we carried out an extensive and iterative com-
pilation of TWEAK-Fn14 signaling pathway by literature
mining. Information gathered on protein-protein interac-
tions, posttranslational modiﬁcations, protein transporta-
tion events, and regulation of gene expression, which are
stimulated by TWEAK were compiled into a signaling path-
way using a visualization tool, PathVisio [62]. Our compiled
data will be useful for the scientiﬁc community to explore,
further, the role of TWEAK in diﬀerential disease patho-
genesis, in biomarker development. Using similar approach,
we have also developed signaling pathways on leptin [63]
receptoractivatorfornuclearfactor κBligand(RANKL)[64]
and follicle stimulating hormone (FSH) [65]. In the current
study,wehavegeneratedareactionmapofTWEAKsignaling
pathway, which is available for visualization at NetSlim [66]
(http://www.netpath.org/netslim/), an accessoryresource for
visualization of NetPath pathways [67].
2. Methods
PubMed searches were performed using TWEAK or Fn14
and their alternate names as keywords to retrieve relevant
articles pertaining to TWEAK signaling. The articles were
screened to capture molecular reactions stimulated by
TWEAKinmammaliancellsascomparedtothecorrespond-
ing unstimulated state. Thereafter, with the use of an in-
housedevelopedsoftware,PathBuilder[68]thatenablescon-
version of pathway data into standard community formats,
namely, PSI-MI, BioPAX, and SBML formats, we annotated
biological information and reactions pertaining to TWEAK
signaling. These included protein-protein interactions,
enzyme-substrate reactions, gene regulation events, and also
various activation/inhibition reactions under a TWEAK
stimulus. These data after manual revision were exported to
the NetPath database,(http://www.netpath.org/) ,am a n u a ll y
assembled resource for signaling pathways generated by our
group [67] which provides the criteria for data compilation.
The entire workﬂow is brieﬂy summarized in Figure 1.
2.1. Protein-Protein Interactions. The protein-protein inter-
actions gathered from several experimental platforms were
cataloged from literature into either binary or complex inter-
actions. A binary interaction represents the interaction of
two proteins either in homomeric or heteromeric form.
A complex protein interaction comprises reactions involv-
ing more than two proteins, which again can be either
homomeric or in heteromeric. For every protein-proteinJournal of Signal Transduction 3
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Figure 1: Workﬂow of the study. Articles were screened based on TWEAK stimulus and the molecular events were added to PathBuilder.
Data were then transferred to NetPath repository. With the help of PathVisio tool, the reactions were used to generate the TWEAK signaling
map (http://www.netpath.org/netslim/tweak pathway.html).
interaction, we documented information on subcellular
localization, the experimental method used, the name and
species of cell models, and ﬁnally, the hyperlinked PubMed
identiﬁer for the corresponding publication.
2.2. Catalytic Reactions. We compiled the posttranslational
modiﬁcations under TWEAK stimulus and mapped them
to their corresponding protein sequences in the RefSeq
database. Further, activation or inhibition of the substrate4 Journal of Signal Transduction
in response to the stimulus was also compiled. The not-
able modiﬁcations chosen were phosphorylation, acetyla-
tion, ubiquitination, sumoylation, protein degradation, and
methylation. The mode of amassment was of two types,
directandindirect.Directincludedthosereactionswherethe
enzyme has been reported for the speciﬁc type of protein
(substrate) modiﬁcation. Indirect reactions include those
where the type of modiﬁcation is experimentally proved;
howevernoinformationexistsaboutitsimmediateupstream
enzyme. The features added for the enzyme-substrate reac-
tions include the type of posttranslational modiﬁcation, the
site and residue of each modiﬁcation, the source of protein,
the species used, and cellular localizations of the respective
reaction. Additionally, we have incorporated a PubMed
identiﬁer as a hyperlink pertaining to the reaction.
2.3. Activation-Inhibition Reactions. Several molecules, in-
cluding the Caspases-3, -7, and -8 (CASP3, CASP7 and
CASP8)[ 24], JUN [20, 29, 69, 70], and NIK (MAP3K14)
[52, 71], were activated, whereas STAT1 was inhibited under
TWEAK stimulus [72]. These molecules do not abide by the
enzyme-substrate reactions and protein-protein interaction
parameters as described previously and thus cannot be con-
nected directly to the main frame of the TWEAK pathway
and are referred to as orphan molecules. We have provided
the source of protein, subcellular localization, species, and
cell line in which the activation or inhibition event was
reported. The PubMed identiﬁer hyperlinked for every event
was also provided.
2.4. Protein Translocation Events. Subcellular transportation
events of proteins under the inﬂuence of TWEAK reported
to date, with appropriate Gene Ontology terms, were added
into the PathBuilder tool. These events were selected on the
basis of the posttranslational modiﬁcations, physical inter-
action or regulatory events. A TWEAK stimulus resulting
in subcellular relocalization of proteins was evidenced by
ﬂuorescent microscopy and immunohistochemical studies.
In addition to a particular protein’s altered localization, we
have also documented the source of protein and cell lines
used. The criteria followed were same as mentioned in the
earlier section.
2.5. Gene Expression Data. We have documented genes
whose expressions are regulated by the TWEAK-Fn14 signal-
ing in humans. Such genes that have been identiﬁed by var-
ious groups at the mRNA level were catalogued from DNA
microarray and nonarray-based experiments such as North-
ern blotting, quantitative RT-PCR, or SAGE.
Further, we have included transcription regulators (tran-
scription factors, or their coactivators/corepressors) down-
stream of TWEAK-Fn14 stimulus. Some of these transcrip-
tion regulators are involved in the regulation of the genes
(mentioned above) upon TWEAK signaling. This too has
been documented and depicted in the pathway diagram.
Such transcriptional regulators have been identiﬁed by ap-
proaches such as chromatin immunoprecipitation assays,
electrophoretic mobility shift assays, gene silencing, and
promoter activity assays in TWEAK-Fn14 signaling.
2.6. Selection of Sample and Species Types. Data for protein-
protein interactions, catalytic reactions, and transportation
events were collected from diseased or normal mammalian
sources that include humans and their orthologs. However,
for the gene regulatory reactions, we considered normal
human cells only.
2.7. Generation of the TWEAK-Fn14 Pathway Map. The
manually assembled data in PathBuilder were compiled
and imported into NetPath (explained under methodology)
[67]. A composite map of pathway reactions pertaining
to TWEAK signaling were generated using PathVisio [62]b y
following the NetSlim parameters as have been employed
earlier by our group [66]. NetSlim (http://www.netpath.org/
netslim/) is a tributary of NetPath, which projects or sum-
marizes only stringent reactions pertaining to the speciﬁc
receptor-ligand complex compiled in a particular study,
for example, TWEAK in this case. The criteria for selecting
high conﬁdence reactions for TWEAK pathway are pro-
vided in the NetSlim database (http://www.netpath.org/
netslim/criteria.html).
3. Results and Discussion
We show here for the ﬁrst time in any scientiﬁc repository
a pathway illustration under TWEAK stimulus. Given the
multifunctional properties of TWEAK, we carried out a
comprehensive literature search under TWEAK stimulus
followed by manual amassment, thereafter reviewing and
adding the data into NetPath database [67].
3.1. TWEAK-Stimulated Data in NetPath. Fifty-eight arti-
cles were found relevant to our amassment criteria from
amongst 357 articles published between 1997 and 2011. This
study led to the documentation of 46 unique proteins amid
which 17 were associated with protein-protein interactions,
20 involved in enzyme-substrate reactions, 13 involved in
activation-inhibition reactions, and 8 were identiﬁed to be
translocated from cytoplasm to nucleus. There were 28 genes
identiﬁed to be diﬀerentially regulated under TWEAK stim-
ulus in human systems. An overview of the TWEAK
pathway in “NetPath” is summarized in Figure 2,w h i c h
c a nb ea c c e s s e df r o mhttp://www.netpath.org/pathways?
path id=NetPath 26.
3.2. TWEAK-Stimulated Signaling Pathway under NetSlim.
The data for visualization of TWEAK signaling pathways
were obtained after ﬁltering NetPath data using NetSlim
parameters. A total of 36 molecules involved in 42 reac-
tions are visually depicted in the TWEAK pathway in
NetSlim. The map generated is provided in Figure 3 and
can be downloaded from http://www.netpath.org/netslim/
tweak pathway.html. The pathway illustration is also ac-
cessible at wikipathways from http://www.wikipathways.org/
index.php/Pathway:WP2036.Journal of Signal Transduction 5
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Figure 2: Illustration of the TWEAK page in NetPath. The image provides an outline of the TWEAK pathway as visualized in the NetPath
webpage. The ﬁgure shows the statistical details of TWEAK pathway-based reactions (right upper corner). Under, “Molecules involved in
TWEAK signaling pathway”, each molecule has been linked to its respective NetPath page. Tabs have been provided which leads to the details
of the “pathway authority,” “curators,” and “comments” tab—where the users can provide their feedback and the reaction tabs. “Access to
data” indicates links to the events regulated by TWEAK. The pathway can be downloaded from the three standard formats provided at the
bottom of the page.
3.3. Data Availability and Reactions. The TWEAK data in
NetPath are available freely and can be used by the scientiﬁc
community. The data are represented in various standard
exchange formats that include Biological PAthway eXchange
(BioPAX) [73], Systems Biology Markup Language (SBML)
[74] and Proteomics Standards Initiative Molecular Inter-
action (PSI-MI) [75] language formats. The PSI-MI is a
communitystandardlanguageformolecularinteractiondata
u s e df o rd a t ac o m p a r i s o na n de x c h a n g e .H o w e v e r ,S B M Li s
a machine readable format for representing biological
models. BioPAX is another standard language that has
features compatible with SBML and PSI-MI formats. The
TWEAK signaling representation can be downloaded from
the NetSlim database in various formats, such as “gpml”,
“GenMAPP”, “png”, and “pdf”. The gene regulation data are
made available in tab-limited and Microsoft Excel formats.
3.4. Summary of the TWEAK Pathway Reactions. Ap a t h w a y
module is deﬁned as an established cascade of events that
takes place inside a cell that has no deﬁned boundaries and is
part of a generic network. Some well-known modules are the
NF-κB, MAPK, the JNK pathways and the PI3K/AKT path-
way modules. A schematic model of the TWEAK pathway
with identiﬁed pathway modules is represented in Figure 3.6 Journal of Signal Transduction
TNFSF12 TNFSF12
TNFSF12
TNFRSF12A
TRAF3 TRAF5 TRAF2 TRAF2
BIRC2
Lysosomal
degradation
Stabilization
of MAP3K14
RELB
TNF
CASP3 CASP7
CASP8
CASP8
FADD
TNF
CHUK
RELB
CTNNB1
GSK3B
AKT2
AKT1
Atrophy
Ubiquitin
proteosome
pathway
skeletal
muscle cells
TRIM63
MAPK1
MAPK3
MAPK14
MAPK8
MAPK9
JUN
Degradation
RELA
MAP3K7
HDAC1 RELA
Protein-protein interaction
Protein-protein dissociation
Acetylation
Deacetylation
Phosphorylation
Dephosphorylation
Sumoylation
Desumoylation
Ubiquitination
Deubiquitination
Methylation
Demethylation
Palmitoylation
Proteolytic cleavage
Transport
Induced activation
Induced catalysis
Plasma membrane
Cytoplasm
Extracellular
Endoplasmic reticulum
Golgi apparatus
Mitochondrion
Nucleus
mRNA Ligand
Receptor
RAC1
RIPK1
TNFRSF1
CHUK
IKBKB
CTNNB1
MAPK14
TRAF1
BIRC3
PM
CY
EC
EN
ER
GO
MT
NU
CY CY
NU NU
CY CY
NU NU
CY
NU
Proliferation
(osteoblasts)
Proliferation
(endothelial cells)
Proliferation
(endothelial cells)
Proliferation
(myotubes)
(renal tubular cells)
Apoptosis
(tumor cells)
DeP
Protein
Protein
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
Translocation
Endosome
Auto catalysis
CCL5 TNF MMP9 IL6 CCL2 CCL5
Protein
Enzyme complex
EC
CY
NFκ-BIB
NFκ-BIA
NFκ-B1
NFκ-B1 NFκ-B2
NFκ-B2
Inhibited in
Leads to through unknown mechanism
Positive regulation of gene expression
Negative regulationof gene expression
Inhibition
Figure 3: TWEAK signaling pathway: illustration of the TWEAK signaling pathway as visualized in NetSlim web page. Each molecule
is linked to its corresponding page in NetPath. Each reaction is linked to its respective PubMed citation. Dashed arrows represent the
downstream reactions leading to the corresponding events while the solid arrows indicate the direct association between the indicated
molecules. Gene symbol(s) has been used to denote proteins in the pathway map (refer to Synonymous for common names).
The TWEAK-Fn14 complex binds to the TRAF molecules,
TRAF 1, 2, 3, and 5. However, the downstream signaling
cascade(s) that proceeds upon the association of TWEAK-
Fn14 complex and TRAF 1/3/5 (TRAF1, TRAF3, TRAF5)i s
unavailable due to the lack of published studies to date. It
was possible to decipher the downstream events following
the formation of the TRAF2-cIAP1 (BIRC2) complex. This
complex possibly undergoes Cathepsin B mediated degrada-
tion. The degradation of the TRAF2-cIAP1 complex leads to
the stabilization of NIK and activation of the noncanonical
NF-κBpathwayasrepresentedinthemodel.Thedegradation
of the TRAF2-cIAP1 complex also leads to the activation
of the caspase pathway resulting in the apoptosis of tumor
cells [11, 27]. Ikner and Ashkenazi [11] have shown that
TWEAK activates apoptosis through the formation of a
RIP1-FADD-caspase8 complex by TNFα mediated signaling,
wherein cIAP1 plays a crucial role. A possible role of
TWEAK has been reported in bone and cartilage damage.
Inﬁbroblast-likesynoviocytes,TWEAKactivatesTRAF2and
cIAP2 proteins which in turn activate the MMP9 expression
[76]. Experimental evidence indicates that TWEAK-Fn14
complex formation leads to the activation of p38 (MAPK14),Journal of Signal Transduction 7
ERK1/2 (MAPK3/MAPK1), JNK1/2 (MAPK8/MAPK9), and
TAK1 (MAP3K7). No evidence has been obtained from
existing literature for further direct downstream targets of
p38 and ERK1/2. However, the activation of TAK1 leads
further to the downstream activation of the NF-κB/p65/p50
pathway. Also, RAC1 has been reported to interact directly
with the TWEAK-Fn14 complex leading to activation of the
NF-κB pathway. Activation of AKT via phosphorylation has
been observed under TWEAK stimulus with an exception in
the case of skeletal muscle [41]. AKT phosphorylation leads
further to the inactivation of GSK3β resulting in an increase
in levels of phospho-GSK3β and active (dephosphorylated)
β-catenin1 (CTNNB1). The cytoplasmic accumulation of
active β-catenin1 results in its nuclear translocation [14].
In addition to binding of TWEAK with Fn14, we have
also documented the binding of CD163 [30]a n dD R 3[ 28]
with TWEAK. Since the interaction between TWEAK and
DR3 remains controversial [28, 29] and the downstream
consequences of a possible TWEAK-CD163 interaction
remain to be explored, the pathway illustration does not
elaborate on the downstream events for these interactions.
4. Conclusions
The ever increasing experimental data on the various mole-
cular events taking place following ligand-receptor inter-
actions, in this case between TWEAK and Fn14, make it
essential to have a repository for the data and also to create
a signaling pathway summary. Our current work, which
incorporates the TWEAK-signaling pathway data into “Net-
Path”, would open avenues for further studies of TWEAK-
associated proteins and related disorders, such as cancers
and autoimmune diseases. To our understanding, this study
compiles for the ﬁrst time TWEAK induced signaling events;
these include (i) the inactivation of GSK3β followed by
dissociation of β-catenin1 [14], (ii) the proapoptotic nature
ofTWEAKmediatedthroughtheexpressionofTNFα,whic h
further leads to the activation of caspase8 [11], and (iii) the
association between TWEAK and cIAP proteins (1 and 2)
[11, 76]. We believe that our data will be informative in
therapeutic studies, in selecting/pathological events and the
simultaneous production of blocking agents. Importantly,
the “NetPath” repository is dynamic and will allow a pro-
gressive update of relevant data, as more published literature
is introduced. In addition to the direct usage of the data
storedinthe“NetPath”database,datacanalsobeexportedto
other databases, enabling comparison and sharing amongst
multiple databases, especially those which have compatible
language formats, such as BioPAX [73]. Despite the minimal
amount of data, ours can also be used in the overlay of
various high-throughput data enabling pathway analysis
and can be accessed by any pathway resource to generate
a customized pathway. We are currently working on the
features in “NetPath”, which are incompatible with BioPAX,
especially the ontology hierarchy that has been proposed by
the BioPAX group [73]. To our knowledge, our compilation
of data in “NetPath” will allow, for the ﬁrst time for any
available scientiﬁc repository, a comprehensive study of the
TWEAK pathway and its potential biomedical applications.
Abbreviations
BioPAX: Biological PAthway eXchange
PSI-MI: Proteomics Standards Initiative for Molecular
Interaction
SBML: Systems Biology Markup Language
TNFα: Tumor necrosis factor
IFN-γ: Interferon gamma
STAT-1: Signal transducer and activator of transcription
1, 91kDa
HDAC-1: Histone deacetylase 1
GSK3β: Glycogen synthase kinase 3 beta
FOXO1a: Forkhead box O1
MTOR: Mechanistic target of rapamycin
(serine/threonine kinase)
RAC1: Ras-related C3 botulinum toxin substrate 1
p38: Mitogen-activated protein kinase 14
AKT1: v-akt murine thymoma viral oncogene
homolog 1
AKT2: v-akt murine thymoma viral oncogene
homolog 2
TRAF1: TNF receptor-associated factor 1
TRAF2: TNF receptor-associated factor 2
TRAF3: TNF receptor-associated factor 3
TRAF5: TNF receptor-associated factor 5
TNF: Tumor necrosis factor
RIPK1: Receptor (TNFRSF)-interacting
serine-threonine kinase 1
RELA: v-rel reticuloendotheliosis viral oncogene
homolog A
RELB: v-rel reticuloendotheliosis viral oncogene
homolog B
CASP3: Caspase3
CASP7: Caspase 7
CASP8: Caspase 8
IKBKB: Inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase beta.
Synonymous Names (Gene Symbol:
Common Name)
(1) Tumor necrosis factor superfamily, member 12
(TNFSF12): TNF-related Weak inducer apoptosis
(TWEAK).
(2) Tumor necrosis factor receptor superfamily, member
12A (TNFRSF12A): FGF-inducible 14 (Fn14).
(3) Tumor necrosis factor receptor superfamily, member
25 (TNFRSF25): Death receptor 3 (DR3).
(4) Baculoviral IAP repeat containing 2 (BIRC2): Cellu-
lar Inhibitors of Apoptosis 1 (cIAP1).
(5) Mitogen-activated protein kinase kinase kinase 14
(MAP3K14): NF-kappa-beta-inducing kinase (NIK).
(6) Conserved helix-loop-helix ubiquitous kinase
(CHUK): IKappa Kinase alpha (IKKα).
(7) Nuclear factor of kappa light polypeptide gene en-
hancer in B-cells 2 (p49/p100) (NFKB2): Nuclear
factor kappa/p52 (p52).8 Journal of Signal Transduction
(8) Mitogen-activated protein kinase 9 (MAPK9): Mito-
gen-activated protein kinase 9 (JNK2).
(9) Mitogen-activated protein kinase 8 (MAPK8): JUN
N-terminal kinase (JNK).
(10) Mitogen-activated protein kinase 7 (MAP3K7): TGF
beta activated kinase 1 (TAK1).
(11) Extracellular regulated kinase 1 (ERK1): Mitogen-
activated protein kinase 3 (MAPK3).
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